Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Lexicon

- PMLiVE

Novo Nordisk gives up on inflammation R&D

Follows disappointing trial results for arthritis drug

- PMLiVE

Genzyme continues MS drug rollout across EU

Lemtrada and Aubagio now available in Republic of Ireland

- PMLiVE

Novo Nordisk debuts diabetes combo in Mexico

Requires fewer daily injections than current insulin treatment

- PMLiVE

TiGenix appoints Dr Marie Paule Richard

She takes on role as chief medical officer and brings experience from Aicuris and Crucell

- PMLiVE

Sanofi/Regeneron’s alirocumab ‘cuts cardiovascular events’

Data presented at ESC Congress demonstrates lower rates of cardiac death, stroke and more

- PMLiVE

Team Novo Nordisk to compete in The Tour of Britain

World’s first all-diabetes pro-cycling team will cycle over 1,300km in eight days

- PMLiVE

Takeda: No link between Actos and bladder cancer

Ten-year study backs safety of diabetes drug

- PMLiVE

Merck enlists celebrity chef in Hispanic diabetes campaign

Leticia Moreinos Schwartz will help get healthy eating message to Latin Americans

- PMLiVE

Novo launches diabetes campaign in Copenhagen

Follows introduction of ‘Cities Changing Diabetes’ programme in Mexico

- PMLiVE

FDA gives green light to Genzyme’s oral Gaucher drug

Oral therapy Cerdelga is set to complement intravenous Cerezyme

- PMLiVE

Illumina partners with pharma majors on cancer diagnostic

Will work with AstraZeneca, Janssen and Sanofi to develop gene sequencing tool

- PMLiVE

‘Tentative’ US approval for Lilly/Boehringer’s Lantus copy

Full FDA recommendation for insulin is dependent on lawsuit filed by Sanofi

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links